ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.04
-0.07%
US Tech 100
19,270.00
-0.54%
S&P 500
5,693.31
-0.33%
US Dollar vs CAD
1.43098
0.10%
Bitcoin
87,641.40
0.87%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Rigel Pharmaceuticals Inc (RIGL) Share Price

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
18.39
-0.59
(-3.11%)
At close: March 27 3:00PM
Delayed by 15 minutes
18.39
0.00
( 0.00% )
After Hours: 3:30PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
18.39
Bid
18.03
Ask
19.98
Volume
184,711
18.35 Day's Range 19.97
7.4843 52 Week Range 29.82
Market Cap
328.5M
Previous Close
18.98
Open
19.51
Last Trade
5
@
19.3
Last Trade Time
15:34:16
Financial Volume
US$ 3,548,879
VWAP
19.2131
Average Volume (3m)
243,404
Shares Outstanding
17,862,958
Dividend Yield
-
PE Ratio
18.77
Earnings Per Share (EPS)
0.98
Revenue
179.28M
Net Profit
17.49M

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rigel.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was US$18.98. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of US$ 7.4843 to US$ 29.82.

Rigel Pharmaceuticals currently has 17,862,958 shares outstanding. The market capitalization of Rigel Pharmaceuticals is US$339.04 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of 18.77.

Ask ADVFN Intelligence (AI)

RIGL Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
8 hours ago
RIGL (-3.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 19 2025
RIGL (-3.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 19 2025
RIGL (-3.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 19 2025
RIGL (-3.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 19 2025
RIGL (-3.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 10 2025
RIGL (-3.11%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
March 10 2025
RIGL (-3.11%)

Form 8-K - Current report
Edgar (US Regulatory)
March 10 2025
RIGL (-3.11%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.86-9.1851851851920.252118.3730978719.88249696CS
4-4.25-18.772084805722.6423.518.3725549520.48165503CS
121.398.176470588241724.515.524340420.55263365CS
262.0712.683823529416.3229.8213.570525091920.21296203CS
524.0928.601398601414.329.827.484358609912.5871436CS
156-13.21-41.803797468431.632.756.4203136512.7445954CS
2602.8918.645161290315.5556.4240294322.88876282CS

RIGL - Frequently Asked Questions (FAQ)

What is the current Rigel Pharmaceuticals share price?
The current share price of Rigel Pharmaceuticals is US$ 18.39
How many Rigel Pharmaceuticals shares are in issue?
Rigel Pharmaceuticals has 17,862,958 shares in issue
What is the market cap of Rigel Pharmaceuticals?
The market capitalisation of Rigel Pharmaceuticals is USD 339.04M
What is the 1 year trading range for Rigel Pharmaceuticals share price?
Rigel Pharmaceuticals has traded in the range of US$ 7.4843 to US$ 29.82 during the past year
What is the PE ratio of Rigel Pharmaceuticals?
The price to earnings ratio of Rigel Pharmaceuticals is 18.77
What is the cash to sales ratio of Rigel Pharmaceuticals?
The cash to sales ratio of Rigel Pharmaceuticals is 1.83
What is the reporting currency for Rigel Pharmaceuticals?
Rigel Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Rigel Pharmaceuticals?
The latest annual turnover of Rigel Pharmaceuticals is USD 179.28M
What is the latest annual profit for Rigel Pharmaceuticals?
The latest annual profit of Rigel Pharmaceuticals is USD 17.49M
What is the registered address of Rigel Pharmaceuticals?
The registered address for Rigel Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Rigel Pharmaceuticals website address?
The website address for Rigel Pharmaceuticals is www.rigel.com
Which industry sector does Rigel Pharmaceuticals operate in?
Rigel Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PRTGPortage Biotech Inc
US$ 10.90
(131.42%)
1.42M
ASTIAscent Solar Technologies Inc
US$ 2.79
(55.87%)
168.35k
SNSESensei Biotherapeutics Inc
US$ 0.5801
(34.66%)
9.11M
RNAZTransCode Therapeutics Inc
US$ 0.66
(26.92%)
3.01M
ULYUrgent ly Inc
US$ 5.90
(23.43%)
7.78k
LGMKLogicMark Inc
US$ 0.0382
(-25.10%)
16.57M
SUGPSU Group Holdings Ltd
US$ 0.699
(-24.72%)
3.87k
PSTVPlus Therapeutics Inc
US$ 1.15
(-24.34%)
1.2M
DRCTDirect Digital Holdings Inc
US$ 1.06
(-20.30%)
2.31M
BGLCBioNexus Gene Lab Corporation
US$ 0.2505
(-16.28%)
144.74k
LGMKLogicMark Inc
US$ 0.0382
(-25.10%)
16.57M
DMNDamon Inc
US$ 0.0402
(-9.87%)
13M
LYTLytus Technologies Holdings PTV Ltd
US$ 0.11
(-6.78%)
12.95M
SNSESensei Biotherapeutics Inc
US$ 0.5801
(34.66%)
9.11M
ARBBARB IOT Group Ltd
US$ 0.7979
(14.15%)
6.08M

RIGL Discussion

View Posts
dcaf7 dcaf7 11 months ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 11 months ago
RIGL under $2
👍️0
Monksdream Monksdream 12 months ago
RIGL under $2
👍️0
dcaf7 dcaf7 12 months ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 1 year ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 1 year ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 2 years ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 2 years ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 2 years ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 2 years ago
Better be good.
👍️0
bme bme 2 years ago
Ugly.
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
base
👍️0
bme bme 2 years ago
What a shoot! Amazing.
👍️0
bme bme 2 years ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 2 years ago
nice fins
👍️0
The Night Stalker The Night Stalker 2 years ago
gem
👍️0
The Night Stalker The Night Stalker 2 years ago
gem
👍️0
The Night Stalker The Night Stalker 2 years ago
easy
👍️0
bme bme 2 years ago
Nice spike AH today.
👍️0
bme bme 2 years ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 2 years ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 2 years ago
quite the dip
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
bme bme 2 years ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 2 years ago
beauty
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Expect Q4 filing this week?
👍️0
bme bme 2 years ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 years ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 years ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 years ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 years ago
RIGL news out
👍️0
bme bme 2 years ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 years ago
Just like ABQQ. Right?
👍️0
subslover subslover 2 years ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 years ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 years ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 years ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 years ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 years ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

NASDAQ
RIGL
Rigel Pharmaceuticals
TG
SYBN
State Street Global Advi...
USOTC
AILIP
Ameren Illinois (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads